Astragalus membranaceus therapy in patients with spinocerebellar ataxia type 3
Chungmin Chiu, Wenling Cheng, Tatsung Lin, Huiju Chang, Minhui Tseng, Yujun Chang, Shihli Su, Chiaju Lee, Henhong Chang, Chinsan Liu · 2026
Read Astragalus membranaceus therapy in patients with spinocerebellar ataxia type 3 by Chungmin Chiu, Wenling Cheng, Tatsung Lin, Huiju Chang, Minhui Tseng, Yujun Chang, Shihli Su, Chiaju Lee, Henhong Chang, Chinsan Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541599.txt.
Description
Chungmin Chiu and colleagues tested an old herb against a nerve-damage marker in spinocerebellar ataxia type 3. Published in 2026, the triple-blind switch-over trial took in 32 patients with SCA3, the most common passed-down balance-center ataxia. Each patient took Astragalus membranaceus or dummy pills for three months, paused a month, then switched.
Twenty-three patients finished the trial. Within herb treatment, the nerve marker dipped a bit and insulin rose, but the tuned head-to-head match-up found no clear herb-versus-dummy gap in the marker, and marker shifts did not track insulin. No clear shifts appeared in related growth-factor measures. Later-stage patients showed larger marker swings in early-look checks. The authors call the findings early and idea-sparking, not proof the herb works.
Catalog record
| CREATOR | Chungmin Chiu, Wenling Cheng, Tatsung Lin, Huiju Chang, Minhui Tseng, Yujun Chang, Shihli Su, Chiaju Lee, Henhong Chang, Chinsan Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |